Pertussis epidemiology in Australia over the decade 1995–2005 – trends by region and age group
DOI:
https://doi.org/10.33321/cdi.2007.31.18Keywords:
pertussis, disease surveillance, immunisationAbstract
Important changes have occurred in the National Immunisation Program for pertussis during the decade 1995–2005, including the introduction of acellular pertussis vaccine for all doses, removal from the schedule of the booster dose at 18 months, and the introduction of a booster dose for adolescents. In addition, the coverage of pertussis vaccine at 12 and 24 months has substantially increased as recorded by Australian Bureau of Statistics surveys and the Australian Childhood Immunisation Register. There were 75,458 notifications nationally between 1995 and 2005, with little change in the annual number of notifications at the national level but with periodic epidemics, which varied among states and territories and dramatic changes in the age distribution of notified cases. Pertussis is well controlled in the 1–4 and 5–9 year age groups, and the highest annual notification rates continue to be in infants under 6 months of age. Adolescents aged 10–19 years had high notification rates in all states and territories, over this period, but 63% of notifications are now in the 20–59 year age range. Following the introduction of a fifth dose for adolescents, the current focus should be on protecting infants too young to be vaccinated and further defining the true morbidity of the disease in the elderly population. Commun Dis Intell 2007;31:205–215.
Downloads
References
Brotherton J, McIntyre P, Puech M, Wang H, Gdding H, Hull B, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2001 to 2002. Commun Dis Intell 2004;28 Suppl 2:S1–S116.
Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001;108:E81.
Hethcote HW, Horby P, McIntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 2004:22;2181–2191.
Lister S, McIntyre PB, Burgess MA, O’Brien ED. Immunisation coverage in Australian children: a systematic review 1990–1998. Commun Dis Intell 1999;23:145–170.
Communicable Diseases Network Australia. Interim surveillance case definitions for the Australian National Notifiable Disease Surveillance System. Canberra: Communicable Diseases Network Australia; 2004. Version 1.
Allen CJ, Ferson MJ. Notification of infectious diseases by general practitioners: a quantitative and qualitative study. Med J Aust 2000;172:325–328.
McIntyre P, Gidding H, Gilmour R, Lawrence G, Hull B, Horby P, et al. Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell 2002;Suppl:1–111.
Torvaldsen S, McIntyre P. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J 2003;22:956–959.
Brotherton JML, McAnulty J. A pertussis epidemic in NSW: how epidemiology reflects immunisation policy. NSW Public Health Bulletin 2003;14:77–81.
Rank C. Epidemiologic impact and vaccine effectiveness following an adolescent pertussis vaccination program in New South Wales [thesis]. Sydney: University of Sydney; 2006.
Tan T, Trindale E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005;24:S10–S18.
Poynten IM, Hanlon M, Irwig L, Gilbert GL. Serological diagnosis of pertussis: Evaluation of IgA against whole cell and specific Bordetella pertussis antigens as markers of recent infection. Epidemiol Infect 2002;128:161–167.
Le T, Cherry JD, Chang S, Knoll MD, Lee ML, Barenkamp S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis 2005;190:535–544.
Nagel J, Poot-Scholtens EJ. Serum IgA antibody to Bordetella pertussis as an indicator of infection. J Med Microbiol 1983;16:417–426.
Ward JI, Cherry JD, Chang S, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555–1563.
Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, Jennings CE, et al. Infant pertussis: who was the source. Pediatr Infect Dis J 2004;23;985–989.
Brotherton J, Wang H, Schaffer A, Quinn H, Menzies R, Hull B, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003–2005. Commun Dis Intell 2007;31. In press.
De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Douville-Fradet M, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182:174–179.
Edwards K, Freeman DM. Adolescent and adult pertussis: disease burden and prevention. Curr Opin Pediatr 2006;18:77–80.
Thomas PF, McIntyre PB, Jalaludin BB. Survey of pertussis morbidity in adults in western Sydney. Med J Aust 2000;173:74–76.
Elliot E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 2004;23:246–252.
Schellekens J, Wirsing von Konig CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J 2005;24 Suppl:S19–S24.
National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing, 2003.
Santibanez TA, Zimmerman RK. Immunizations in adulthood. Prim Care 2002;29:649–665.
Zimmerman RK, Ball JA. Vaccinations in adults: missed opportunities. Am Fam Physician 1998;58:853–854.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2007 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
